Among 1429 individuals, although patients with T2DM co-existent with NAFLD had a higher prevalence of artery hypertension, waist circumference, BMI, DBP, increased level of FBG, lipids (TG, TC, LDL-C), liver enzymes (ALT, AST), TP, ALB, prealbumin, γ-GT, WBC, lymphocyte (%), lymphocyte, eosinophilic granulocyte (%), basophilic granulocyte (%), RBC, HGB, TBIL, UA and eGFR compared with those without NAFLD, there was no significant difference in the prevalence of AMI between the two groups (32.7% vs 33.1%, p = 0.872) (Additional file 1: Table S1). This evidence concerns the gene CYGB and metabolic dysfunction-associated steatotic liver disease.